JLM-BioCity presents: 

“What Global Companies Seek in Jerusalem Bio Innovation”

Sunday, January 29th, 2017 

Azrieli College of Engineering,  Auditorium 001,  building 4 (the old building)

with guest speakers:

Guido Pardo-Roques – President & CEO, Philips Israel

Jonathan Goldstein -Director, Corporate Research & Ventures, Boston Scientific Corporation

• Marc Feiglin – Hd Technology Scouting, Partnerships & Program Management,                                  Merck Israel

• Ilya Budik – Boehringer Ingelheim 

JLM-BioCity has invited several global health care companies to present what they are looking for in Israeli Bio Innovation, what their wish list is and how to work with them. This event is important for every bio entrepreneur and professional to be better acquainted with an important sector of the investment scene. It is also an opportunity to show these global life science companies that Jerusalem is rapidly becoming the focus of Israeli life science startups.

The life science sector in Israel is one of the fastest growing industries, with an average of 17% annual growth over the last decade and sales of $ 6 billion in 2015. Israel’s life science exports are set to double in the next five years, fueled by the R&D activities. There are over 1,000 life science companies in Israel with over 140 of them based in Jerusalem. Global companies offer a major contribution to investment in Israeli life science. Over 15 global companies have R&D centers in Israel with technology scouts, company acquisition and VC funding scouting the Israeli life science community. Over the last decade, over 15 major acquisitions took place in Jerusalem with Oridion Medical being acquired by Covidien and Omrix by Johnson and Johnson.


Moderators:  Yaron Suissa – JLM-BioCity.org 

17:30 Registration & Networking

18:00 Greetings 

• Debbie Shalev, Head, <a>Pharmaceutical Engineering, Azrieli College of Engineering</a></a>

• Shai Melcer, Executive Director, <a href=”http://www.biojerusalem.org.il/”>Bio-Jerusalem 

                       “Why Jerusalem is Israel’s Bio Capital”

• JLM-Bio Innovations – Short Pitchs from JLM Bio Companies

 – > Phytor, a Novel Drug Against Pancreatic Cancer

 – > Triox Nano,  S.M.A.R.T (Stimuli Multi Adjusted Responsive Technology) nano machines against Triple Negative Breast cancer

– > Salignostics Ltd, Next Generation Saliva based Pregnancy Detection Kit

– > NIMD,, A Painless Non Invasive Procedure for Eliminating Breast Cancer Tumors

– > Vectored Photonics,  An Ubiquitous Smart-Home Multi-Dimensional Health,  Care, Companionship,  and Protection system for Elderly


• Guido Pardo-Roques – President & CEO, Philips Israel

• Jonathan Goldstein -Director, Corporate Research & Ventures, Boston Scientific Corporation

• Marc Feiglin – Hd Technology Scouting, Partnerships & Program Management,                                  Merck Israel

• Ilya Budik Boehringer Ingelheim 

               Questions & Answers

19:30 – 20:30 Networking 

For further information for entrepreneurs on the Global companies:

1) The focus on innovation for Philips Israel is in the following areas:

 • Continuum of care & Disease management

 • Patient diagnosis Sensing and monitoring

 • Emerging Imaging Modalities

 • Drug delivery and drug-device combinations

 • Digital Health, Healthcare IT, Mobile Apps

 • Minimally invasive device technologies

For Philips Israel, entrepreneurs are invited to address Sanara Ventures, our investment platform together with Teva   http://sanaraventures.com/

2) For the Merck Group, entrepreneurs can get further information from 2 sites:

· Our Innovation site which has some of our programs: http://www.merckgroup.com/en/innovation/innovation.html

· The site for our corporate venture fund, Merck Ventures http://merck-ventures.com/

3) Boston Scientific Corporation provides support for researchers to conduct investigator sponsored original research that is of interest to Boston Scientific and the medical community. For further information,   http://www.bostonscientific.com/en-US/investigator-sponsored-research/overview.html      or  contact  jonathan.goldstein@bsci.com 

4) Boehringer Ingelheim  is focused on (1)  Cardiovascular (2) Oncology (3) Respiratory (4) Central Nervous System (5) Metabolic Diseases  (6) Immunology (7) Animal Diseases 

For further information are their activities of R&D https://www.boehringer-ingelheim.com/innovation  

For information on how to work with Boehringer Ingelheim  https://www.boehringer-ingelheim.com/partnering/partnering-interests 

JLM-BioCity (JBNF-BioMed) is delighted to announce this event is sponsored by Azrieli College of Engineeringand AtoBe – Azrieli College of Engineering Startup Accelerator

The presentations will all be given in English.

RVSP to reserve your place. There will be a 20 NIS entrance fee to the event.


LOCATION: Auditorium 001, on the first floor (using , in the old building 4.

About our speakers:

Guido Pardo-Roques – President & CEO Philips Israel 
                                         CEO, Philips Medical Systems Technologies (PMSTL) 
                                         Sr Director, CT Business Development 

Guido Benjamin Pardo-Roques is the president and CEO of Philips Israel and CEO of Philips Medical System Technologies which constitutes the Israel Commercial and Industrial branches of the multinational corporation Royal Philips Electronics. He is also Chairman of the Medical Equipment forum, Board Member of  IAESI (Israel Association of Electronics and Software Industries),  Board Member of IATI (Israel Advanced Technology Industries) and member of the  Technion Board of Governors. PMSTL , which includes industrial sites in Haifa,  Petach TIkvah and Nethanya,  is the flagship of Royal Philips interests in Israel and  focuses on research, development, manufacturing and customer support of advanced CT  and PET/CT scanners, Advanced Visualization and Imaging Clinical Applications, Digital Healthcare. Employees in Philips focus in Clinical Science, System Engineering, HW and SW development. 

Guido joined Elscint’s CT Division in 1980; in 1988 he was appointed to Project Manager of the CT Twin, the world’s first multislice scanner, a breakthrough product that changed the CT imaging landscape for the 20 years to follow. In 1993, Guido was appointed to R&D Manager of Elscint CT and in this function, he was one of the leaders that positioned the Haifa facility as the major CT detection site in the world. In 2001 the activity  was acquired by Philips.

In 2014, Pardo Roques contributed to the creation of  Sanara Ventures, which includes a Healthcare Technological Incubator under the auspices of the Israel Chief Scientist, in the Israel Ministry of Economy with the participation of Philips and Teva.

Guido holds BSc and MSc from the Technion in Haifa, and MBA from the Haifa University. In 1997, for the commercial success of the CT Twin, Guido, together with the development team, received the Rothschild Prize for Innovation.

Jonathan Goldstein –-Director, Corporate Research & Ventures, Boston Scientific Corporation

Jonathan  focuses on strategic VC investments in Europe and Israel. He has been working for Boston Scientific Corporation (BSC) since 2012, interfacing with Israeli technology and projects, and generating collaborations across the spectrum of BSC’s R&D, Venture and Business Development functions. Jonathan also manages the Corporate Research Division’s Worldwide Scouting Team, supporting Divisional and Corporate teams in identifying relevant next generation technologies and companies for the company’s pipeline.

Jonathan started out as a strategy consultant for Metapraxis Ltd. in London in the early 90s, working with blue-chip companies such as Unilever, Kleinwort Benson and S.G. Warburg. Since moving to Israel in 1995, he has focused on the biomedical field, working initially at one of Israel’s key hi-tech investment banks, followed by extensive periods in Business Development at some of Israel’s most innovative biomedical startups. Jonathan was as a member on the Advisory Board of the award-winning Meytav Technology Incubator, and, until recently, was the Israel Editor of Medical Device Daily of the US.

Jonathan holds a BSc. in Chemistry & Biochemistry from Imperial College, London, and an MBA from the University of London.

Marc Feiglin – Head Scouting & Partnering, Israel at Merck Group

Marc is the head of Technology Scouting in Israel for Merck Group of Darmstadt, Germany. In this role, Marc is looking for partnerships and investments that complement Merck’s activities in the Healthcare, Performance Materials and Life Science arenas.  Marc joined Merck Group in June 2015 and relocated to Israel with his family from the east coast of the US.

Prior to joining Merck, Marc worked for 13 years at Tecan Group, a Swiss manufacturer of laboratory instrumentation. While at Tecan, he held a variety of roles including Head of the eFluidics Business, Chief Technology Officer, and Head of Life Sciences Corporate Development splitting his time between Silicon Valley and Zurich.

Prior to Tecan, Marc worked for 10 years in New Jersey for the American pharmaceutical company Merck & Company (known as MSD in Israel and not related to his current employer), where he managed numerous groups responsible for implementing new technologies for assisting in the early stages of drug discovery.

Marc holds an MBA jointly awarded by New York University Stern School of Business, London School of Economics and Political Science, and Hautes Etudes Commerciales School of Management (Paris) and a BS degree in Biology from the University of Michigan.

Ilya Budik – Boehringer Ingelheim

Ilya is an accomplished executive in the biotech industry with experience in guiding strategic product and business development in both established and emerging companies. He has effectively recruited capital from angels, venture, and strategic partner financing; established R&D and clinical teams; led international projects; and ran due diligence on prospective technologies. He maintains extensive relationships in the biotech and high-tech industry, tech transfer organizations, VC’s, and professional organizations.

Ilya brings to the table executive management experience with biomedical start-ups in Israel and finance at Johnson & Johnson in the US. Previously, he served as CEO at NeuroQuest, a Trendlines Medical Portfolio company, where he led the clinical validation of blood-based immune biomarkers for Alzheimer’s and ALS diseases through the recruitment of a management team with industry recognized leaders in business and clinical development, secured $1 million in financing from private and institutional investors, and partnered with key international players in the industry. Previously, he managed business development at MND Diagnostics.

Ilya studied finance and biochemistry at Miami University of Ohio, contributing to research efforts in biochemistry and organic chemistry at Miami University, Ohio State University, and the University of Tennessee and completed the Lahav Executive Training program for Healthcare Entrepreneurship at Tel Aviv University.